Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14448485 | 0.89 | MMP13 (0.56) | MMP13SMN1; SMN2POLBLMNAALDH1A1 | |
| SCHEMBL14448480 | 0.89 | MMP13 (0.73) | MMP13SMN1; SMN2POLBL3MBTL1PDE2A | |
| SCHEMBL14448479 | 0.87 | MMP13 (0.58) | MMP13SMN1; SMN2KMT2AMEN1L3MBTL1 | |
| SCHEMBL14468896 | 0.86 | MMP13 (0.47) | MMP13SMN1; SMN2POLBLMNAALDH1A1 | |
| SCHEMBL14448658 | 0.84 | MMP13 (0.45) | MMP13SMN1; SMN2POLBLMNAALDH1A1 | |
| SCHEMBL14448466 | 0.83 | MMP13 (0.44) | MMP13SMN1; SMN2POLBLMNAALDH1A1 | |
| SCHEMBL14448657 | 0.83 | MMP13 (0.49) | MMP13SMN1; SMN2POLBLMNAALDH1A1 | |
| SCHEMBL14448520 | 0.83 | MMP13 (0.44) | MMP13SMN1; SMN2POLBLMNAALDH1A1 | |
| SCHEMBL14448624 | 0.83 | XDH (0.49) | MMP13SMN1; SMN2POLBLMNAALDH1A1 | |
| SCHEMBL14448499 | 0.82 | MMP13 (0.52) | MMP13SMN1; SMN2POLBALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | MMP13, MMP9, ADAMTS13 | MMP13 1/4885SMN1; SMN2 1621/4885POLB 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.